5/20
11:17 am
goss
Gossamer Bio, Inc. (NASDAQ: GOSS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Gossamer Bio, Inc. (NASDAQ: GOSS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
5/14
04:16 pm
goss
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference [Yahoo! Finance]
Low
Report
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference [Yahoo! Finance]
5/14
04:01 pm
goss
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
Low
Report
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
5/10
04:30 pm
goss
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
5/8
10:31 am
goss
Gossamer Bio, Inc. (NASDAQ: GOSS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $4.00 price target on the stock.
Low
Report
Gossamer Bio, Inc. (NASDAQ: GOSS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $4.00 price target on the stock.
5/7
04:51 pm
goss
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
5/7
04:01 pm
goss
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
5/6
01:26 pm
goss
Gossamer Bio, Inc. (NASDAQ: GOSS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Gossamer Bio, Inc. (NASDAQ: GOSS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
5/6
08:44 am
goss
Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications
Medium
Report
Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications
5/6
07:39 am
goss
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications [Yahoo! Finance]
Medium
Report
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications [Yahoo! Finance]
5/6
07:30 am
goss
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
Medium
Report
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
5/3
08:09 am
goss
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine [Yahoo! Finance]
Low
Report
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine [Yahoo! Finance]
5/3
08:02 am
goss
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
Medium
Report
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
4/26
07:20 am
goss
Gossamer Bio Decline Means Insider Profits Down To US$17k [Yahoo! Finance]
Medium
Report
Gossamer Bio Decline Means Insider Profits Down To US$17k [Yahoo! Finance]
4/5
08:03 am
goss
Gossamer Bio, Inc. (NASDAQ: GOSS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $4.00 price target on the stock.
Low
Report
Gossamer Bio, Inc. (NASDAQ: GOSS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $4.00 price target on the stock.
3/27
01:09 pm
goss
Gossamer Bio, Inc. (NASDAQ: GOSS) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $15.00 price target on the stock.
Low
Report
Gossamer Bio, Inc. (NASDAQ: GOSS) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $15.00 price target on the stock.
3/12
07:43 am
goss
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors [Yahoo! Finance]
Low
Report
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors [Yahoo! Finance]
3/12
07:31 am
goss
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
Low
Report
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
3/7
11:50 am
goss
Should You Buy Gossamer Bio (GOSS) After Golden Cross? [Yahoo! Finance]
Neutral
Report
Should You Buy Gossamer Bio (GOSS) After Golden Cross? [Yahoo! Finance]
3/6
11:58 am
goss
Gossamer Bio, Inc. (NASDAQ: GOSS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.
Low
Report
Gossamer Bio, Inc. (NASDAQ: GOSS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.
3/6
11:58 am
goss
Gossamer Bio, Inc. (NASDAQ: GOSS) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $9.00 to $8.00. They now have a "buy" rating on the stock.
Low
Report
Gossamer Bio, Inc. (NASDAQ: GOSS) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $9.00 to $8.00. They now have a "buy" rating on the stock.
3/6
08:44 am
goss
Gossamer Bio, Inc. (NASDAQ: GOSS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Gossamer Bio, Inc. (NASDAQ: GOSS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
3/5
07:44 am
goss
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
3/5
07:31 am
goss
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
Medium
Report
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update